Cytokine-in-Adjuvant Steering of the Immune Response Phenotype to HIV-1 Vaccine Constructs: Granulocyte-Macrophage Colony-Stimulating Factor and TNF-α Synergize with IL-12 to Enhance Induction of Cytotoxic T Lymphocytes

Journal of Immunology

Volumn 158, Issue 8, 1997, Pages 3947-3958

  Ahlers, Jeffrey D ^a   Dunlop, Nancy ^c   Alling, David W ^b   Nara, Peter L ^c   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; PEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; IMMUNITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOLECULAR GENETICS; MOUSE;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DRUG SYNERGISM; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031569457     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. 8+ cytotoxic T cells by immunization with punned HIV-1 envelope protein in ISCOMs. Nature 344:873.
2. 8+ cytotoxic T lymphocyte responses. J. Immunol. 148:2357.
3. 8+ CTL in vivo with peptide vaccine constructs. J. Immunol. 152:549.
4. Ahlers, J. D., N. Dunlop, C. D. Pendleton, M. Newman, P. L. Nara, and J. A. Berzofsky. 1996. Candidate HIV type1 multideterminant cluster peptide-P18 MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization. AIDS Res. Hum. Retroviruses 12:259.
5. Walker, C., M. Selby, A. Erickson, D. Cataldo, J.-P. Valensi, and G. Van Nest. 1992. Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway. Proc. Natl. Acad. Sci. USA 89: 7915.
6. Sher, A., R. T. Gazzinelli, I. P. Oswald, M. Clerici, M. Kullberg, E. J. Pearce, J. A. Berzofsky, T. R. Mosmann, S. L. James, H. C. Morse III, and G. M. Shearer. 1992. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol. Rev. 127:183.
7. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
8. Tao, M.-H., and R. Levy. 1993. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755.
9. Blankenstein, T., D. A. Rowley, and H. Schreiber. 1991. Cytokines and caner: experimental systems. Curr. Opin. Immunol. 3:694.
10. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223.
11. Golumbek, P. T., A. J. Lazenby, H. I. Levitsky, L. M. Jaffee, H. Karasuyama, M. Baker, and D. M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713.
12. Stoppacciaro, A., C. Melani, M. Parenza, A. Mastracchio, C. Bassi, C. Baroni, G. Parmiani, and M. P. Colombo. 1993. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon γ. J. Exp. Med. 178:151.
13. Zitvogel, L., H. Tahara, P. D. Robbins, W. J. Storkus, M. R. Clarke, M. A. Nalesnik, and M. T. Lotze. 1995. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J. Immunol. 155:1393.
14. Chen, L., S. Ashe, W. A. Brady, I. Hellström, K. E. Hellström, J. A. Ledbetter, P. Mcgowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
15. 8+ T cells by B7-transfected melanoma cells. Science 259:368.
16. Yang, G., K. E. Hellström, I. Hellström, and L. Chen. 1995. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154:2794.
17. Noguchi, Y., E. C. Richards, Y.-T. Chen, and L. J. Old. 1995. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92:2219.
18. Irvine, K. R., J. B. Rao, S. A. Rosenberg, and N. P. Restifo. 1996. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol. 156:238.
19. Strominger, J. L. 1995. Peptide vaccination against cancer? Nat. Med. 1:1140.
20. Martinotti, A., A. Stoppacciaro, M. Vagliani, C. Melani, F. Spreafico, M. Wysocka, G. Parmiani, G. Trinchieri, and M. P. Colombo. 1995. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol. 25:137.
21. Nanda, N. K., and E. E. Sercarz. 1995. Induction of anti-self-immunity to cure cancer. Cell 82:13.
22. + T cells producing IL-2 or IL-4. J. Immunol. 148:1031.
23. + T cells from T cell receptor transgenic mice. J. Exp. Med. 176:1091.
24. Abehsira-Amar, O., M. Gibert, M. Joliy, J. Thófze, and D. Lj. Jankovic. 1992. IL-4 plays a dominant role in the differential development of Th0 into Th1 and Th2 cells. J. Immunol. 148:3820.
25. Gajewski, T. F., and F. W. Fitch. 1988. Anti-proliferative effect of IFN-γ in immune regulation. I. IFN-γ inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J. Immunol. 140:4245.
26. Manetti, R., P. Parronchi, M. G. Giudizi, M.-P. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1199.
27. + T cells. J. Immunol. 154:5071.
28. + T cells to enhance priming for IFNγ production and diminishes IL-4 inhibition of such priming. Proc. Natl. Acad. Sci. USA 90:10188.
29. Swain, S. L., G. Huston, S. Tonkonogy, and A. Weinberg. 1991. Transforming growth factor-β and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J. Immunol. 147:2991.
30. Perez, V. L., J. A. Lederer, A. H. Lichtman, and A. K. Abbas. 1995. Stability of Th1 and Th2 populations. Int. Immunol. 7:869.
31. Szabo, S. J., N. G. Jacobson, A. S. Dighe, U. Gubler, and K. M. Murphy. 1995. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity 2:665.
32. Wu, C. Y., C. E. Demeure, M. Gately, F. Podlaski, H. Yssel, M. Kiniwa, and G. Delespesse. 1994. In vitro maturation of human neonatal CD4 T lymphocytes. I. Induction of IL-4 producing cells after long-term culture in the presence of IL-4 plus either IL-2 or IL-12. J. Immunol. 152-1141.
33. + T cell subset expression. Int. Immunol. 6:785.
34. Pfeiffer, C., J. Stein, S. Southwood, H. Ketelaar, A. Sette, and K. Bottomly. 1995. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J. Exp. Med. 181:1569.
35. Pfeiffer, C., J. Murray, J. Madri, and K. Bottomly. 1991. Selective activation of Th1-and Th2-like cells in vivo: response to human collagen IV. Immunol. Rev. 123:65.
36. Reiner, S. L., Z.-E. Wang, F. Hatam, P. Scott, and R. M. Locksley. 1993. Th1 and Th2 cell antigen receptors in experimental leishmaniasis. Science 259:1457.
37. Bretscher, P. A., G. Wei, J. N. Menon, and H. Bielefeldt-Ohmann. 1992. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 257:539.
38. + functional responses by peptide dose in Th1 and Th2 subsets expressing the same transgenic antigen receptor. Cell. Immunol. 148:357.
39. + T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J. Exp. Med. 181:1081.
40. Sarzotti, M., D. S. Robbins, and P. M. Hoffman. 1996. Induction of protective CTL responses in newborn mice by a murine retrovirus. Science 271:1726.
41. Burstein, H. J., C. M. Shea, and A. K. Abbas. 1992. Aqueous antigens induce in vivo tolerance selectively in IL-2-and IFN-γ-producing (Th1) cells. J. Immunol. 148:3687.
42. Forsthuber, T., H. C. Yip, and P. V. Lehmann. 1996. Induction of Th1 and Th2 immunity in neonatal mice. Science 271:1728.
43. Chen, Y., J.-i. Inobe, R. Marks, P. Gonnella, V. K. Kuchroo, and H. L. Weiner. 1995. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 376:177.
44. Pearlman, E., J. W. Kazura, F. E. Hazlett, Jr., and W. H. Boom. 1993. Modulation of murine cytokine responses to mycobacterial antigens by helminth-induced T helper 2 cell responses. J. Immunol. 151:4857.
45. Kullberg, M. C., E. J. Pearce, S. E. Hieny, A. Sher, and J. A. Berzofsky. 1992. Infection with Schistosoma mansoni alters Th1/Th2 cytokine responses to a non-parasite antigen. J. Immunol. 148:3264.
46. 8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance. Proc. Natl. Acad. Sci. USA 90:948.
47. Corry, D. B., S. L. Reiner, P. S. Linsley, and R. M. Locksley. 1994. Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J. Immunol. 153:4142.
48. Kuchroo, V. K., M. Prabhu Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
49. Ahlers, J. D., C. D. Pendleton, N. Dunlop, A. Minassian, P. L. Nara, and J. A. Berzofsky. 1993. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. J. Immunol. 150:5647.
50. Kawamuru, H., S. A. Rosenberg, and J. A. Berzofsky. 1985. Immunization with antigen and interleukin-2 in vivo overcomes Ir genetic low responsiveness. J. Exp. Med. 162:381.
51. Good, M. F., D. Pombo, M. N. Lunde, W. L. Maloy, R. Halenbeck, K. Koths, L. H. Miller, and J. A. Berzofsky. 1988. Recombinant human interleukin-2 (IL-2) overcomes genetic nonresponsiveness to malaria sporozoite peptides: correlation of effect with biological activity of IL-2. J. Immunol. 141:972.
52. Hsieh, C.-S., S. E. Macatonia, A. O'Garra, and K. M. Murphy. 1995. T cell genetic background determines default T helper phenotype development in vitro. J. Exp. Med. 181:713.
53. Myers, G., S. F. Josephs, J. A. Berzofsky, A. B. Rabson, T. F. Smith, and F. Wong-Staal. 1989. Human Retroviruses and AIDS 1989. Los Alamos National Laboratory, New Mexico.
54. Nara, P. L., W. C. Hatch, N. M. Dunlop, W. G. Robey, L. O. Arthur, M. A. Gonda, and P. J. Fischinger. 1987. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res. Hum. Retroviruses 3:283.
55. Hosoi, S., T. Borsos, N. Dunlop, and P. L. Nara. 1990. Heat-labile, complement-like factor(s) of animal sera prevent(s) HIV-1 infectivity in vitro. J. Acquired Immune Defic. Syndr. 3:366.
56. Takahashi, H., J. Cohen, A. Hosmalin, K. B. Cease, R. Houghten, J. Cornette, C. DeLisi, B. Moss, R. N. Germain, and J. A. Beraofsky. 1988. An immunodominant epitope of the HIV gp160 envelope glycoprotein recognized by class I MHC molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 85:3105.
57. Hu-Li, J., J. Ohara, C. Watson, W. Tsang, and W. E. Paul. 1989. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J. Immunol 142:800.
58. Wynn, T. A., D. Jankovic, S. Hieny, K. Zioncheck, P. Jardieu, A. W. Cheever, and A. Sher. 1995. IL-12 exacerbates rather than suppresses T helper 2-dependent pathology in the absence of endogenous IFN-γ. J. Immunol. 154:3999.
59. Güler, M. L., J. D. Gorham, C.-S. Hsieh, A. J. Mackey, R. G. Steen, W. F. Dietrich, and K. M. Murphy. 1996. Genetic susceptibility to Leishmania: IL-12 responsiveness in Th1 cell development. Science 271:984.
60. Wenner, C. A., M. L. Güler, S. E. Macatonia, A. O'Garra, and K. M. Murphy. 1996. Roles of IFN-γ in IL-12-induced T helper cell-1 development. J. Immunol. 156:1442.
61. Macatonia, S. E., T. M. Doherty, S. C. Knight, and A. O'Garra. 1993. Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-γ production. J. Immunol. 150:3755.
62. + T cells. J. Immunol. 154:4915.
63. Nabavi, N., G. J. Freeman, A. Gault, D. Godfrey, L. M. Nadler, and L. H. Glimcher. 1992. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 360:266.
64. Shu, U., M. Kiniwa, C. Y. Wu, C. Maliszewski, N. Vezzio, J. Hakimi, M. Gately, and G. Delespesse. 1995. Activated T cells induced inteleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur. J. Immunol. 25:1125.
65. Lynch, D. H., and R. E. Miller. 1994. Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J. Exp. Med. 179:31.
66. Noguchi, M., Y. Nakamura, S. M. Russell, S. F. Ziegler, M. Tsang, X. Cao, and W. J. Leonard. 1993. Interleukin-2 receptor γ chain: a functional component of the interleukin-7 receptor. Science 262:1877.
67. Xiang, Z., and H. C. J. Ertl. 1995. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2:129.
68. Kwak, L. W., H. A. Young, R. W. Pennington, and S. D. Weeks. 1996. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA 93:10972.
69. Disis, M. L., H. Bernhard, F. M. Shiota, S. L. Hand, J. R. Gralow, E. S. Huseby, S. Gillis, and M. A. Cheever. 1996. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccinces. Blood 88: 202.
70. Jäger, E., M. Ringhoffer, H. P. Dienes, M. Arand, J. Karbach, D. Jäger, C. Ilsemann, M. Hagedorn, F. Oesch, and A. Knuth. 1996. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer 67:54.
71. Morris, S. C., K. B. Madden, J. J. Adamovicz, W. C. Gause, B. R. Hubbard, M. K. Gately, and F. D. Finkelman. 1994. Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J. Immunol. 152:1047.
72. Bliss, J., V. Van Cleave, K. Murray, A. Wiencis, M. Ketchum, R. Maylor, T. Haire, C. Resmini, A. K. Abbas, and S. F. Wolf. 1996. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J. Immunol. 156:887.
73. + T cells requires the coordinate action of interleukin-12 and interferon-γ and is inhibited by transforming growth factor-β. Eur. J. Immunol. 24:793.
74. + T cells through an effect on antigen-presenting cells. J. Immunol. 154:2578.
75. Clerici, M., and G. M. Shearer. 1994. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol. Today 15:575.
76. Clerici, M., D. R. Lucey, J. A. Berzofsky, L. A. Pinto, T. A. Wynn, S. P. Blatt, M. J. Dolan, C. W. Hendrix, S. F. Wolf, and G. M. Shearer. 1993. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 262:1721.
77. Clerici, M., T. A. Wynn, J. A. Berzofsky, S. P. Blatt, C. W. Hendrix, A. Sher, R. L. Coffman, and G. M. Shearer. 1994. Role of imerleukin-10 (IL-10) in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus (HIV-1). J. Clin. Invest. 93:768.
78. Landay, A. L., M. Clerici, F. Hashemi, H. Kessler, J. A. Berzofsky, and G. M. Shearer. 1996. In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J. Infect. Dis. 173:1085.
79. Bender, A., U. Amann, R. Jäger, M. Nain, and D. Gemsa. 1993. Effect of granulocyte/macrophage colony-stimulating factor on human monocytes infected with influenza A virus. J. Immunol. 151:5416.
80. Foli, A., M. W. Saville, M. W. Baseler, and R. Yarchoan. 1995. Effects of the Th1 and Th2 stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication. Blood 8:2114.